Biotech Values

[biomaven0]

I think a head-to-head trial with Sutent would be more compelling and clinically relevant.

It's tough to show superiority over Sutent, so now you are dealing with a non-inferiority trial.

Clinically, given the Aveo drug seems to have a comparable side-effect profile to that of Nexavar, I believe going head-to-head with Nexavar makes a lot of sense. Plenty of time to compare with Sutent down the road. In the meantime, I can see a lot of clinicians going with the more tolerable drug assuming it looks anywhere near comparable to Sutent.

Peter